




AF 2100

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. 17151 (PC23251A)	
Applicant(s): Mark A. Dombroski, et al.					
Application No. 10/649,236	Filing Date August 27, 2003	Examiner Patricia L. Morris	Customer No. 23389	Group Art Unit 1625	Confirmation No. 6195
Invention: DIAMOND TRIFLUORO-TRIAZOLO-PYRIDINES ANTI-INFLAMMATORY COMPOUNDS					
 COMMISSIONER FOR PATENTS:					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	29 -	33 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	1 -	3 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1013/SSMP <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
 _____ <i>Signature</i>			Dated: April 12, 2005		
Peter I. Bernstein Registration No. 43,497 SCULLY, SCOTT, MURPHY & PRESSER			<div style="border: 1px solid black; padding: 5px;"> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</p> <p style="text-align: center;"><u>April 12, 2005</u></p> <p style="text-align: center;">(Date)</p> <p style="text-align: center;"></p> <p style="text-align: center;"><i>Signature of Person Mailing Correspondence</i></p> <p style="text-align: center;">Peter I. Bernstein</p> <p style="text-align: center;"><i>Typed or Printed Name of Person Mailing Correspondence</i></p> </div>		
PIB/RLB:ej cc:					



Corres. and Mail
BOX AF

RESPONSE UNDER 37 C.F.R. §1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1625

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Mark A. Dombroski, et al.

Examiner: Patricia L. Morris

Serial No: 10/649,236

Art Unit: 1625

Filed: August 27, 2003

Docket: 17151 (PC23251A)

For: DI AND TRIFLUORO-TRIAZOLO-
PYRIDINES ANTI-INFLAMMATORY
COMPOUNDS

Dated: April 12, 2005

Confirmation No.: 6195

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. §1.116

Sir:

In response to the Official Action dated January 12, 2005, Applicants respectfully request entry of the following amendment in the above-identified case.

There are no amendments made to the specification.


Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 8 of this paper.

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 12, 2005


Peter I. Bernstein